Gator Bio’s Post

Earlier this week, Prof Alan Boyd had the pleasure of attending the 2-day Fierce Biotech Summit in Boston. A big thank you to the organizers at Fierce Pharma, and to the insightful speakers and panelists for leading some great discussions on the future of the biotech industry. 📧 If you didn't get the chance to connect with Alan at the Summit, or would like to learn more about how Boyds can support your path to drug approval, reach out at info@boydconsultants.com. Fierce Life Sciences Events #FierceBiotechSummit #BiotechInnovation #FierceBiotech #Biotech2024

I’m looking forward to presenting at Biotech X EU on AstraZeneca’s approach in leveraging real-world evidence in our efforts to speed up drug discovery and deliver medicines to patients faster. If you are attending Biotech X EU, please join the session on October 9th for a discussion on where we are currently with the utility of real-world evidence and how the next generation of real-world data will further optimize development decisions.     #BiotechX #OncologyDataScience #RealWorldEvidence #DrugDiscovery

I'm excited to share that I'll be presenting at the iPSC Drug Development & Manufacturing Summit in Boston next week from Oct 1st-3rd. My session will focus on "Integrative Approaches for Prime Editing Drug Discovery Across Disease Indications Using iPSC-Derived Model Systems." Check out the agenda for the event here: https://lnkd.in/ePbt77H8 #iPSCSummit #PrimeEditing #GeneEditing #CRISPR #StemCells #DrugDevelopment

🚀 Last week, the InVivo Biosystems team had the incredible opportunity to attend the Precision Evolution Global Drug Discovery & Preclinical Summit, a game-changing event where our very own Sarah Cheesman, Ph.D., VP of Strategic Partnerships, moderated an expert panel on overcoming bottlenecks to attaining IND approval — a critical topic for revolutionizing the path to new therapies. We were thrilled to find that so many attendees were already aware of the power of zebrafish and 𝘊. 𝘦𝘭𝘦𝘨𝘢𝘯𝘴 as valuable models in preclinical development! 🐟🪱 These models are truly gaining recognition for their potential to accelerate drug discovery and provide earlier insights into therapeutic efficacy and safety. On top of that, we made fantastic new connections and came away energized to continue advancing research with our 𝑹𝒂𝒑𝒊𝒅𝑮𝒆𝒏™ 𝒑𝒍𝒂𝒕𝒇𝒐𝒓𝒎, pushing the frontiers of preclinical testing. Here’s to continuing the momentum and working together to bring innovative solutions to life! 💡 #DrugDiscovery #PreclinicalResearch #Pharma #Biopharma #Zebrafish #Celegans #Biotech #Innovation #InVivoBiosystems #RapidGen #PrecisionEvolutionSummit

A few years back, Tom Neyarapally taught me that to solve for complex problems in healthcare, I should characterize patients across the continuum of their care (pre/post diagnosis, at index date of med admin, at progression, etc), take inventory of those available data, and then figure out what each of those patients had in common. The work he and the team at Archetype Therapeutics, Inc. are doing to accelerate drug discovery is fantastic and rooted in that thinking. Very cool video from them below: https://lnkd.in/dMWnsNi2

We're excited to announce the strategic partnership between Vipergen, www.vipergen.com, with Aurigene Pharmaceutical Services ltd, https://lnkd.in/e9_X74y By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, the companies will integrate and enhance their end-to-end discovery solution, by offering expedited hit identification. The partnership aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds either in a living cell or on a purified drug target protein. Access the full story here: https://lnkd.in/eANxvqeX Commenting on the partnership Akhil Ravi, CEO of Aurigene said that “The partnership with Vipergen emphasizes our commitment to accelerating innovation and customer centric approach. Vipergen’s proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergen the ideal strategic partner for us." Nils Jakob Vest Hansen, Ph.D., CEO of Vipergen, added that “we are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene’s drug discovery capabilities and global reach makes a perfect match for Vipergen. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers. #collaboration #partnership #media #drugdiscovery #screening #DNA #encoded #library #innovation #CRDMO #aurigene  #Vipergen

We're excited to announce our strategic partnership with Vipergen ApS to provide DNA encoded library (DEL) screening and integrated drug discovery services. The partnership aims to accelerate innovation in drug discovery by increasing success rates and reducing timelines through screening a billion+ small-molecule compounds either in a living cell or on a purified drug target protein. Access the full story here! https://lnkd.in/g7s7MhJ8 Commenting on the partnership our CEO, Akhil Ravi said that “The partnership with Vipergen emphasizes our commitment to accelerating innovation and customer centric approach. Vipergen’s proven track record, with more than 90 partnerships with big pharma and biotech companies, and their streamlined hit finding platform, makes Vipergen the ideal strategic partner for us." Nils Jakob Vest Hansen, Ph.D., CEO of Vipergen, added that “we are excited to partner with Aurigene, a global CRDMO focused on customer service. Aurigene’s drug discovery capabilities and global reach makes a perfect match for Vipergen. I am looking forward to a successful partnership, and to offering our proprietary technologies to global customers.   #collaboration #partnership #media #drugdiscovery #screening #DNA #encoded #library #innovation #CRDMO #aurigene  

Thoughts on this? >> Cartesian clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharma #productmarketing #pharmaceutical #healthcare

Meet Dr JIA LU: Principal Scientist in the Target Discovery Team. In our latest Meet the Team blog, we spoke with Jia to learn more about the challenges associated with the development of new molecular glue degraders and how GlueSEEKER represents a unique opportunity to design and evaluate novel protein-protein interactions.   Jia also shared updates on our internal TPD-focused programs and partnerships with industry-leading pharma companies, where we are deploying our SITESEEKER platform across a range of therapeutic areas. Find the full interview here: https://rb.gy/6w34mg #MolecularGlues #TPD #Drug Discovery

Happy to share RoukenBio story and highlight how this innovative Scottish CRO continues to bring new cell-based assays on the market to improve drug discovery development. Can't wait to see what they will deliver next! https://lnkd.in/exgH5uKf